Albireo Pharma Inc (ALBO) Received its Third Buy in a Row

By Jason Carr

After H.C. Wainwright and Needham gave Albireo Pharma Inc (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma Inc today and set a price target of $69. The company’s shares closed on Friday at $28.96.

According to, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.5% and a 34.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma Inc with a $60.33 average price target, a 108.3% upside from current levels. In a report issued on February 28, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $62 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $39.35 and a one-year low of $19.10. Currently, Albireo Pharma Inc has an average volume of 42.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384.